DaVita Inc. (NYSE:DVA) Short Interest Update

DaVita Inc. (NYSE:DVA) saw a large drop in short interest in October. As of October 15th, there was short interest totalling 4,300,000 shares, a drop of 14.9% from the September 30th total of 5,050,000 shares. Approximately 5.4% of the company’s stock are short sold. Based on an average daily volume of 711,500 shares, the short-interest ratio is currently 6.0 days.

Wall Street Analysts Forecast Growth

DVA has been the topic of several analyst reports. TD Cowen increased their price target on DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. UBS Group lifted their target price on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Truist Financial upped their price target on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a report on Monday, October 7th. Finally, Bank of America lifted their price objective on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $159.00.

DaVita Stock Performance

NYSE DVA traded up $1.63 during midday trading on Tuesday, hitting $158.68. The company had a trading volume of 58,283 shares, compared to its average volume of 799,328. DaVita has a fifty-two week low of $75.47 and a fifty-two week high of $168.50. The stock has a market cap of $13.31 billion, a price-to-earnings ratio of 16.73, a P/E/G ratio of 0.90 and a beta of 0.87. The firm has a fifty day simple moving average of $158.18 and a two-hundred day simple moving average of $145.85. The company has a quick ratio of 1.12, a current ratio of 1.16 and a debt-to-equity ratio of 9.94.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.47 by $0.12. The firm had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.15 billion. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.08 EPS. Equities analysts forecast that DaVita will post 9.99 earnings per share for the current fiscal year.

Insider Transactions at DaVita

In related news, COO Michael David Staffieri sold 9,539 shares of the stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $150.03, for a total value of $1,431,136.17. Following the transaction, the chief operating officer now owns 241,945 shares in the company, valued at approximately $36,299,008.35. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, COO Michael David Staffieri sold 9,539 shares of DaVita stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $150.03, for a total value of $1,431,136.17. Following the completion of the sale, the chief operating officer now owns 241,945 shares of the company’s stock, valued at approximately $36,299,008.35. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Joel Ackerman sold 64,029 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the transaction, the chief financial officer now directly owns 111,481 shares in the company, valued at $17,286,243.86. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 173,482 shares of company stock valued at $27,387,069 in the last three months. Corporate insiders own 2.00% of the company’s stock.

Institutional Trading of DaVita

A number of large investors have recently bought and sold shares of the stock. Harvard Management Co. Inc. bought a new stake in shares of DaVita in the 2nd quarter worth about $55,115,000. Lazard Asset Management LLC grew its holdings in shares of DaVita by 147.3% during the first quarter. Lazard Asset Management LLC now owns 256,872 shares of the company’s stock worth $35,460,000 after purchasing an additional 153,008 shares during the last quarter. Andra AP fonden increased its stake in shares of DaVita by 9.0% in the second quarter. Andra AP fonden now owns 192,300 shares of the company’s stock valued at $26,647,000 after buying an additional 15,800 shares in the last quarter. abrdn plc raised its holdings in shares of DaVita by 1.2% in the third quarter. abrdn plc now owns 189,065 shares of the company’s stock valued at $30,719,000 after buying an additional 2,180 shares during the last quarter. Finally, Jupiter Asset Management Ltd. lifted its position in DaVita by 146.7% during the 1st quarter. Jupiter Asset Management Ltd. now owns 187,177 shares of the company’s stock worth $25,840,000 after buying an additional 111,311 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.